Lantern Pharma

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantern Pharma reports robust Q4 earnings, unveils strategic drug plans

Lantern Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic drug development plans, and a focus on innovation.
The company faces challenges in a competitive landscape but has opportunities in combination therapies, CNS cancer treatments, and engaging key opinion leaders.
Effective financial management and a clear clinical development roadmap are key strengths for Lantern Pharma.
Balancing financial stability with continued investment in research and development will be crucial for sustained growth.

Lantern Pharma advances AI-driven drug development with strong financial backing

Lantern Pharma's Q1 2023 Earnings Call highlighted significant progress in drug development and financial stability, underpinned by a focus on AI and data analytics.
While facing challenges in managing R&D expenses and industry competition, the company's innovative approach and strong cash position position them well for future growth.
Opportunities abound for Lantern Pharma to further leverage AI, explore partnerships, and advance in critical areas like brain cancer drug discovery.
Overall, Lantern Pharma's strategic focus on technology-driven efficiency and innovation sets a promising trajectory for their future in the pharmaceutical landscape.

Lantern Pharma reports promising Q2 results amidst AI-driven advancements

Lantern Pharma's Q2 2023 performance reflects a mix of financial stability, promising drug candidates, and advancements in AI-driven drug development.
The company's strengths lie in its innovative AI-driven strategy, focus on biology, and cost-effective approach to advancing molecules into trials.
Challenges include optimizing trial enrollment, addressing clinician preferences, and navigating the competitive landscape of AI-driven drug discovery.
Opportunities for Lantern Pharma include presenting new data, exploring combination therapies, and leveraging their fit-for-purpose strategy in oncology for future growth.

Lantern Pharma reports Q3 progress, financial stability, and innovation focus

Lantern Pharma's Q3 2023 earnings call highlighted progress in drug development, financial stability with a cash runway into at least Q3 2025, and a focus on innovation through the RADR platform.
While facing challenges such as a net loss and the need to improve financial performance, the company's strengths in pipeline development and technological innovation position them for future growth.
Opportunities lie in leveraging the RADR platform for accelerated drug development, data accumulation in 2024, and pursuing strategic initiatives supported by a strong cash position.
Overall, Lantern Pharma's earnings call reflects a balance of achievements, challenges, and opportunities that shape their trajectory in the pharmaceutical industry.

Lantern Pharma reports Q4 loss, eyes collaborations for growth

Lantern Pharma's Q4 2023 performance reflects a focus on innovation and strategic financial management.
The company's strengths lie in AI-driven drug discovery, diversification efforts, and platform advancements.
Challenges include managing expenses, navigating risks, and ensuring successful execution of growth plans.
Opportunities in collaborations, licensing, and leveraging their platform as a currency offer avenues for expansion.

Lantern Pharma reports Q1 loss, advances AI drug development

Lantern Pharma's Q1 2024 earnings call highlighted financial results, AI-driven drug development, and collaborations.
The company's focus on accelerating drug development and expanding into new indications shows promise for future growth.
Despite challenges in timelines and trial expansions, Lantern Pharma aims for more efficient drug development processes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its fourth quarter and fiscal year 2022 financial results webcast on Monday, March 20, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET

Signature Bank

SVB Financial Group

Lantern Pharma Inc. LTRN, -13.13% confirmed Monday that it, or any of its subsidiaries, had no exposure to SIVB Financial Group's SIVB, -60.41% Silicon Valley Bank, Silvergate Capital Corp. SI, -11.27% or Signature Bank SBNY, -22.87% . The biopharmaceutical company's statement comes after Lantern's stock plunged 22.4% last week, the second-worst weekly performance since it went public in June 2020, to close Friday at a four-month low.

Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that neither Lantern Pharma Inc. nor any of its subsidiaries had any exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank.

Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced new data for its product candidate LP-100 supporting the development of LP-100 in combination with the class of anticancer agents known as PARP inhibitors (PARPi).

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on March 21, 2023 at 12:00 p.m.

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern's Drug Candidates, Featuring Zoltan Szallasi, M.D.

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has formed a wholly-owned subsidiary, Starlight Therapeutics Inc.

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo M.D., M.Sc., MBA, as Vice President of Clinical Development, and several additional team members.

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has entered into a research and development collaboration with TTC Oncology.

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

Amesite Operating

Inuvo

Remark Hlds

Oblong

Powerbridge Technologies Co Ltd

Predictive Oncology Inc

AI penny stocks provide investors with higher-risk, higher-upside exposure to companies specializing in developing or utilizing artificial intelligence technology. Since these stocks trade at a relatively low price per share and may be relatively unproven, operating in niche areas of the market, there's more to be gained by a correct bet on these stocks.

7 AI Penny Stocks That Could Skyrocket in 2023

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced expansions and updates to RADR®'s product roadmap, which will further enhance its oncology drug discovery capabilities.

Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

DALLAS--( BUSINESS WIRE )--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has received guidance from the United States Food and Drug Administration (FDA) on Lantern's clinical development plans for its LP-184 program. LP-184 has shown nanomolar potency across a range of cancers including several solid tumors and multiple adult and pediatric central nervous system (CNS) cancers. The FDA feedback clears Lantern's path for an IND submission and the targeted initiation of a first-in-human clinical trial in Q2 2023.

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184's Phase 1 Clinical Trial in Q2 2023

DALLAS--( BUSINESS WIRE )--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive form of B-cell non-Hodgkin's lymphoma (NHL) that is typically diagnosed at advanced stages in elderly patients. As nearly all MCL patients acquire resistance and relapse from treatment with standard-of-care (SOC) agents, there is an urgent and unmet clinical need for new and effective therapies to treat MCL.

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

DALLAS--( BUSINESS WIRE )--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it presented new positive preclinical data for its drug candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology Annual meeting.

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting

DALLAS--( BUSINESS WIRE )--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded development of its drug candidate LP-184 to include Triple Negative Breast Cancer (TNBC), one of the most aggressive and malignant forms of breast cancer. New positive preclinical data on the anti-tumor potency of LP-184 for TNBCs was recently presented at the San Antonio Breast Cancer Symposium (SABCS) 2022.

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announces that Panna Sharma, CEO and President, will present at the RHK Capital Disruptive Growth Conference in New York City.

Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET

ProPhase Labs

Fintel reports that ProPhase Labs, Inc. has filed a 13G form with the SEC disclosing ownership of 910,000 shares of Lantern Pharma Inc. (LTRN). This represents 8.4% of the company.

ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results

DALLAS--( BUSINESS WIRE )--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it presented positive preclinical data on the efficacy of its drug candidate LP-184 for glioblastoma (GBM), used alone or in combination with the Food and Drug Administration (FDA) approved agent spironolactone, at the Society for Neuro-Oncology (SNO) annual meeting.

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting

Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - CFO Nicole Leber - Investor Relations Conference Call Participants John Vandermosten - Zacks Research Michael King - EF Hutton [Call Start Abruptly] shortly after the call. We issued a press release after market closed today, summarizing our financial results and progress across the company for the third quarter of 2022.

Lantern Pharma Inc. (LTRN) Q3 2022 Earnings Call Transcript

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.

Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights

Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.

Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET

Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences

Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300

DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.

News for Lantern Pharma Stock (LTRN)